TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
Transcode Therapeutics has raised $6.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in April 2026.
Transcode Therapeutics's investors include National Institutes of Health, Red Cedar Ventures, TRITON FUNDS LLC, National Cancer Institute, CK Life Sciences International.
Transcode Therapeutics is headquartered in Newton, United States.
TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
Transcode Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Transcode Therapeutics — Funding & Investors." VCBacked, April 7, 2026, https://www.vcbacked.co/company/transcode-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Transcode Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/transcode-therapeutics
{{cite web |title=Transcode Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/transcode-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated